arrow
C

Caroline M. Moore

university college london
H指数:68
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improving prostate MRI quality assessment across diverse evaluators and institutional practice through a PI-QUAL v2 lecture: a pilot study

通过PI-QUAL v2讲座提高前列腺MRI质量评估在多样化评估者和机构实践中的质量:一项试点研究

2026-10-290
OAAI
Measuring prostate cancer lesion size on serial MRI during active surveillance: A multi-centre observational study

在主动监测期间通过连续MRI测量前列腺癌病灶大小:一项多中心观察性研究

2026-09-100
PRE
Validating the biological origin of in vivo fractional intracellular volume from VERDICT-MRI in the prostate

验证VERDICT-MRI中前列腺体内细胞内分数体积的生物起源

2026-09-090
OAAI
COMPARISON OF CONTEMPORARY PATIENT SELECTION CRITERIA FOR FOCAL THERAPY: AN ANALYSIS OF 2658 PATIENTS FROM THE PROSPECTIVE HEAT AND ICE REGISTRIES

当代局部治疗患者选择标准的比较:来自前瞻性HEAT和ICE登记研究的2658例患者的分析

2026-05-010
PRE
VALIDATION OF EXISTING RISK STRATIFICATION TOOLS FOR PREDICTING TREATMENT FAILURE AFTER FOCAL THERAPY: AN ANALYSIS OF 3460 PATIENTS FROM THE HEAT AND ICE REGISTRIES

现有风险分层工具在预测局部治疗后治疗失败中的验证:HEAT和ICE登记研究的3 460例患者分析

2026-05-010
PRE
IMPACT OF DIFFERENT PROSTATE CANCER TREATMENT OPTIONS ON BOWEL FUNCTION: A MULTICENTER COHORT ANALYSIS STUDY OF THE TRUENTH GLOBAL REGISTRY (UK DATASET)

不同前列腺癌治疗方式对肠道功能的影响:Truenth全球注册研究(英国数据集)的多中心队列分析研究

2026-05-010
PRE
Utilization of Prediagnostic Prostate Magnetic Resonance Imaging Among Rural Americans: An Analysis of Medicare Claims for Elevated Prostate-Specific Antigen

农村美国人中前列腺癌诊断前磁共振成像的应用:一项基于医疗保险索赔数据的分析,针对前列腺特异性抗原升高的病例

2026-05-010
PRE
The ‘Comparison of diagnostic accuracy of Luminal Index and standard of care MRI for Accelerated deTEction of prostate cancer’ (CLIMATE) trial protocol
2026-01-250
PRE
Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low Uptake

前列腺癌胚系基因检测的地理变异性:一项基于全国性医疗保险索赔数据的研究,显示其采用率较低

2025-12-010
PRE
Claims-Based Analysis of National Utilization Patterns and Regional Variability of Prostate Cancer Ablative Therapies: A Medicare Study

基于理赔数据的分析:前列腺癌消融疗法的国家使用模式及区域差异性——一项医疗保险研究

2025-11-010
PRE
Reply to Francesco Montorsi, Paolo Zauirto, and Giorgio Gandaglia’s Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167–75

回复Francesco Montorsi、Paolo Zauirto和Giorgio Gandaglia的致编辑信:关于Cameron Englman、Busola Adebusoye、Davide Maffei等人撰写的《前列腺癌的磁共振成像引导风险适应主动监测:大型队列研究的更新结果》,发表于《欧洲泌尿学杂志》2025年第88卷第167-175页。

2025-10-070
PRE
Reply to Yuan Du, Dan Liu, and Zhihui Guan’s Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167–75

回复袁杜、刘丹和关志辉的致编辑信:关于Cameron Englman、Busola Adebusoye、Davide Maffei等人。以磁共振成像指导的风险适应主动监测用于前列腺癌:来自一项大型队列研究的更新结果。欧洲泌尿学杂志 2025;88:167–75。

2025-09-180
PRE
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024)

前列腺癌消融治疗的法医学现状:一项国家法律数据库关于医疗事故索赔的分析(1970-2024)

2025-09-010
PRE
Magnetic Resonance Imaging–led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study

前列腺癌的磁共振成像引导的风险适应性主动监测:来自一项大型队列研究的更新结果

2025-05-270
OAAI